<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">I.P. Pavlov Journal of Higher Nervous Activity</journal-id><journal-title-group><journal-title xml:lang="en">I.P. Pavlov Journal of Higher Nervous Activity</journal-title><trans-title-group xml:lang="ru"><trans-title>Журнал высшей нервной деятельности им. И.П. Павлова</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0044-4677</issn><issn publication-format="electronic">3034-5316</issn><publisher><publisher-name xml:lang="en">The Russian Academy of Sciences</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">652108</article-id><article-id pub-id-type="doi">10.31857/S0044467724010062</article-id><article-categories><subj-group subj-group-type="toc-heading"><subject>КЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">11C–methionine PET/CT in meningiomas</article-title><trans-title-group xml:lang="ru"><trans-title>ПЭТ/КТ с использованием 11С–метионина при менингиомах</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Galkin</surname><given-names>M. V.</given-names></name><name xml:lang="ru"><surname>Галкин</surname><given-names>М. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>mgalkin@nsi.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Vikhrova</surname><given-names>N. B.</given-names></name><name xml:lang="ru"><surname>Вихрова</surname><given-names>Н. Б.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>mgalkin@nsi.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Golanov</surname><given-names>A. V.</given-names></name><name xml:lang="ru"><surname>Голанов</surname><given-names>А. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>mgalkin@nsi.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Danilov</surname><given-names>G. V.</given-names></name><name xml:lang="ru"><surname>Данилов</surname><given-names>Г. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>mgalkin@nsi.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Strunina</surname><given-names>Yu. V.</given-names></name><name xml:lang="ru"><surname>Струнина</surname><given-names>Ю. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>mgalkin@nsi.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Burdenko National Medical Research Center of Neurosurgery, Ministry of Healthcare of Russia</institution></aff><aff><institution xml:lang="ru">ФГАУ “НМИЦ нейрохирургии им. академика Н. Н. Бурденко” Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2024-07-10" publication-format="electronic"><day>10</day><month>07</month><year>2024</year></pub-date><volume>74</volume><issue>1</issue><fpage>60</fpage><lpage>68</lpage><history><date date-type="received" iso-8601-date="2025-02-02"><day>02</day><month>02</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2024, Russian Academy of Sciences</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2024, Российская академия наук</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="en">Russian Academy of Sciences</copyright-holder><copyright-holder xml:lang="ru">Российская академия наук</copyright-holder></permissions><self-uri xlink:href="https://innoscience.ru/0044-4677/article/view/652108">https://innoscience.ru/0044-4677/article/view/652108</self-uri><abstract xml:lang="en"><p>Currently, positron emission tomography (PET) is the standard imaging modality in neuro-oncology for gliomas and metastatic lesions. The experience of PET application in meningiomas, the most frequent primary CNS neoplasms, is much less, and the interpretation of the study results has a number of differences. The aim of the study was to evaluate the possibility and peculiarities of PET application in meningiomas based on our own clinical experience and literature review.</p> <p>The study included 70 patients with 77 meningiomas who underwent PET/CT with <sup>11</sup>C-methionine. The mean age at the time of examination was 57.4 years (19–86 years).</p> <p>The main evaluation parameter, the tumor-to-brain ratio (TBR) of <sup>11</sup>C-methionine (<sup>11</sup>C–MET) averaged 3.13 (1.00–10.66). Meningiomas were characterized by high <sup>11</sup>C–MET TBR, with 89.6% of cases having TBR greater than 1.5. In histologically verified WHO grade 1, 2, and 3 meningiomas, the median TBR was 4.06 [3.04, 4.57], 2.32 [2.12, 3.69], and 4.29 [2.60, 5.10] and did not differ significantly between groups. Meanwhile, in histologically unresectable slow-growing or non-growing incidental meningiomas, TBR of <sup>11</sup>C–MET was significantly lower than in WHO grade 1 and 3 meningiomas.</p> <p>There was no significant difference in the accumulation index between irradiated meningiomas with tumor growth control (3.81 [2.97, 3.98]) and recurrence (3.62 [2.60, 4.30]). When irradiated and non-irradiated meningiomas of WHO grade 1, 2 and 3, as well as the combined group of grade 1–3 tumors were compared, no significant differences in <sup>11</sup>C–MET TBR were found.</p> <p>The use of PET/CT in meningiomas has a number of important features. Meningiomas are characterized by high TBR of <sup>11</sup>C–MET. According to our data PET/CT with <sup>11</sup>C–MET does not allow differentiating between meningiomas of different degrees of malignancy – 1, 2 or 3 according to WHO. With effective radiotherapy, meningiomas show partial reduction of TBR or remain stable. Even with prolonged growth control after radiation treatment, meningiomas may still have high TBR of <sup>11</sup>C–MET. When comparing growing and stable meningiomas, irradiated and non-irradiated tumors, no significant differences in TBR of <sup>11</sup>C–MET are found.</p></abstract><trans-abstract xml:lang="ru"><p>В настоящее время позитронно-эмиссионная томография, совмещенная с компьютерной томографией (ПЭТ/КТ), – это стандартный метод визуализации в нейроонкологии при глиомах и метастатическом поражении. Опыт применения ПЭТ/КТ при менингиомах – самых частых первичных новообразованиях ЦНС – значительно меньше, а интерпретация результатов исследований имеет ряд отличий. Целью работы стала оценка возможности и особенностей применения ПЭТ/КТ для определения степени злокачественности менингиом, распространенности, ответа на лучевое лечение и диагностики рецидива и/или постлучевых изменений на основании собственного клинического опыта и обзора литературы.</p> <p>В исследование были включены 70 пациентов с 77 менингиомами, которым была выполнена ПЭТ/КТ с <sup>11</sup>С-метионином. Средний возраст на момент обследования составил 57.4 года (19–86 лет).</p> <p>Основной параметр оценки – индекс накопления (ИН)<sup>11</sup>С-метионина (<sup>11</sup>С–МЕТ) в опухоли – составил в среднем 3.13 (1.00–10.66). Менингиомы характеризовались высоким ИН<sup>11</sup>С–МЕТ, в 89.6% случаев ИН превышал 1.5. В гистологически верифицированных менингиомах 1, 2 и 3-й степени злокачественности по шкале ВОЗ медиана ИН составила 4.06 [3.04; 4.57], 2.32 [2.12; 3.69] и 4.29 [2.60; 5.10] и достоверно не различалась между группами. При этом в нерастущих или медленнорастущих гистологически неверифицированных менингиомах – случайных находках – ИН<sup>11</sup>С–МЕТ был достоверно ниже, чем в менингиомах 1 и 3-й степени.</p> <p>Не было выявлено достоверного различия в ИН между облученными менингиомами с контролем роста опухоли (3.81 [2.97; 3.98]) и рецидивом (3.62 [2.60; 4.30]). При сопоставлении облученных и необлученных менингиом 1, 2 и 3-й степеней злокачественности, а также объединенной группы опухолей 1–3-й степеней достоверных различий в ИН<sup>11</sup>С–МЕТ выявлено не было.</p> <p>Применение ПЭТ/КТ при менингиомах имеет ряд важных особенностей. Менингиомы характеризуются высоким ИН<sup>11</sup>С–МЕТ. По нашим данным, ПЭТ/КТ с <sup>11</sup>С–МЕТ не позволяет различать между собой менингиомы разной степени злокачественности – 1, 2 или 3-й по шкале ВОЗ. При эффективном лучевом лечении и длительном локальном контроле ИН<sup>11</sup>С–МЕТ в менингиомах сохраняется стабильно высоким или происходит невыраженное его снижение. При сопоставлении растущих и нерастущих менингиом, облученных и необлученных опухолей не выявляется достоверных различий в ИН<sup>11</sup>С–МЕТ.</p></trans-abstract><kwd-group xml:lang="en"><kwd>meningioma</kwd><kwd>PET/CT</kwd><kwd>radiopharmaceutical</kwd><kwd>11C-methionine</kwd><kwd>grade of malignancy</kwd><kwd>tumor growth</kwd><kwd>radiotherapy</kwd><kwd>post-radiation changes</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>менингиома</kwd><kwd>ПЭТ/КТ</kwd><kwd>радиофармпрепарат</kwd><kwd>11С-метионин</kwd><kwd>степень злокачественности</kwd><kwd>продолженный рост опухоли</kwd><kwd>радиотерапия</kwd><kwd>постлучевые изменения</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution xml:lang="ru">Минобрнауки России</institution></institution-wrap><institution-wrap><institution xml:lang="en">Ministry of Education and Science of Russia</institution></institution-wrap></funding-source><award-id>075–15–2021–1343</award-id></award-group></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Acker G., Kluge A., Lukas M., Conti A., Pasemann D., Meinert F., Anh Nguyen P.T., Jelgersma C., Loebel F., Budach V., Vajkoczy P., Furth C., Baur A. D.J., Senger C. Impact of 68Ga-DOTATOC PET/MRI on robotic radiosurgery treatment planning in meningioma patients: first experiences in a single institution. Neurosurgical focus. 2019. 46 (6) E9.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Afshar-Oromieh A., Giesel F.L., Linhart H.G., Haberkorn U., Haufe S., Combs S.E., Podlesek D., Eisenhut M., Kratochwil C. Detection of cranial meningiomas: comparison of ⁶⁸Ga-DOTATOC PET/CT and contrastenhanced MRI. European journal of nuclear medicine and molecular imaging. 2012. 39 (9):1409–1415.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Arita H., Kinoshita M., Okita Y., Hirayama R., Watabe T., Ishohashi K., Kijima N., Kagawa N., Fujimoto Y., Kishima H., Shimosegawa E., Hatazawa J., Hashimoto N., Yoshimine T. Clinical characteristics of meningiomas assessed by ¹¹C-methionine and ¹⁸F-fluorodeoxyglucose positron-emission tomography. Journal of neurooncology. 2012. 107 (2):379–386.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Astner S.T., Dobrei-Ciuchendea M., Essler M., Bundschuh R.A., Sai H., Schwaiger M., Molls M., Weber W.A., Grosu A.-L. Effect of 11C-methionine-positron emission tomography on gross tumor volume delineation in stereotactic radiotherapy of skull base meningiomas. Int J Radiat Oncol Biol Phys. 2008. 72 (4):1161–1167.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Campos Neto G.d.C., Amaro Junior E., Weltman E., Malheiros S.M.F., Ferrari B. L., Vitor T., Barboza M.R.F.F. de, Bezerra R.P., Yamaga L.Y.I., Wagner J., Baroni R. H. Comparative analysis of somatostatin analog uptake between successfully irradiated and non-irradiated meningiomas. Einstein (Sao Paulo, Brazil). 2022. 20eAO0104.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Cremerius U., Bares R., Weis J., Sabri O., Mull M., Schröder J.M., Gilsbach J.M., Buell U. Fasting improves discrimination of grade 1 and atypical or malignant meningioma in FDG-PETFasting improves discrimination of grade 1 and atypical or malignant meningioma in FDG-PET. Journal of nuclear medicine: official publication, Society of Nuclear Medicine. 1997. 38 (1):26–30.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Filippi L., Palumbo I., Bagni O., Schillaci O., Aristei C., Palumbo B. Somatostatin receptor targeted PET-imaging for diagnosis, radiotherapy planning and theranos tics of meningiomas: a systematic review of the litera ture. Diagnostics. 2022. 12 (7).</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Grosu A.-L., Weber W.A., Astner S.T., Adam M., Krause B.J., Schwaiger M., Molls M., Nieder C. 11C-methionine PET improves the target volume delineation of meningiomas treated with stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys. 2006. 66 (2): 339–344.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Gudjonsson O., Blomquist E., Lilja A., Ericson H., Bergström M., Nyberg G. Evaluation of the effect of highenergy proton irradiation treatment on meningiomas by means of 11C–L-methionine PET. Eur J Nucl Med. 2000. 27 (12):1793–1799.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Hua L., Hua F., Zhu H., Deng J., Wang D., Luan S., Tang H., Guan Y., Xie Q., Gong Y. The diagnostic value of using 18F-fluorodeoxyglucose positron emission tomography to differentiate between lowand high-grade meningioma. Cancer management and research. 2019. 11:9185– 9193.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Ivanidze J., Roytman M., Lin E., Magge R.S., Pisapia D.J., Liechty B., Karakatsanis N., Ramakrishna R., Knisely J., Schwartz T.H., Osborne J.R., Pannullo S.C. Gallium-68 DOTATATE PET in the evaluation of intracranial meningiomas. Journal of neuroimaging: official journal of the American Society of Neuroimaging. 2019. 29 (5): 650–656.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Jeltema H.-R., Jansen M.R., Potgieser A.R.E., van Asselt A.D.I., Heesters M.A.A.M., van de Hoorn A., Glaudemans A. W.J.M., van Dijk J.M.C. Study on intracranial meningioma using PET ligand investigation during follow-up over years (SIMPLIFY). Neuroradiology. 2021. 63 (11):1791–1799.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Jung I.-H., Chang K.W., Park S.H., Jung H.H., Chang J.H., Chang J.W., Chang W.S. Pseudoprogression and peritumoral edema due to intratumoral necrosis after Gamma knife radiosurgery for meningioma. Scientific Reports. 2022. 12 (1):13663.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Kaul D., Budach V., Wurm R., Gruen A., Graaf L., Habbel P., Badakhshi H. Linac-based stereotactic radiotherapy and radiosurgery in patients with meningioma. Radiation oncology (London, England). 2014. 9:78.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Kessel K.A., Weber W., Yakushev I., Fischer H., Voglhuber T., Diehl C., Straube C., Zimmer C., Wiestler B., Gempt J., Meyer B., Combs S.E. Integration of PET-imaging into radiotherapy treatment planning for low-grade meningiomas improves outcome. European journal of nuclear medicine and molecular imaging. 2020. 47 (6): 1391– 1399.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Kowalski E. S., Khairnar R., Gryaznov A. A., Kesari V., Koroulakis A., Raghavan P., Chen W., Woodworth G., Mishra M. 68Ga-DOTATATE PET-CT as a tool for radiation planning and evaluating treatment responses in the clinical management of meningiomas. Radiation oncology (London, England). 2021. 16 (1):151.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Kriwanek F., Ulbrich L., Lechner W., Lütgendorf-Caucig C., Konrad S., Waldstein C., Herrmann H., Georg D., Widder J., Traub-Weidinger T., Rausch I. Impact of SSTR PET on inter-observer variability of target delineation of meningioma and the possibility of using threshold-based segmentations in radiation oncology. Cancers. 2022. 14 (18).</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Lee J.W., Kang K.W., Park S.-H., Lee S.M., Paeng J.C., Chung J.-K., Lee M.C., Lee D.S. 18F-FDG PET in the assessment of tumor grade and prediction of tumor recurrence in intracranial meningioma. European journal of nuclear medicine and molecular imaging. 2009. 36(10):1574–1582.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Lütgendorf-Caucig C., Pelak M., Flechl B., Georg P., Fossati P., Stock M., Traub-Weidinger T., Marosi C., Haberler C., Zechmeister-Machhart G., Hermsmeyer L., Hug E., Staudenherz A. The trends and significance of SSTR PET/CT added to MRI in follow-up imaging of lowgrade meningioma treated with fractionated proton therapy. Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft … [et al]. 2023. 199 (4): 396–403.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Mitamura K., Yamamoto Y., Norikane T., Hatakeyama T., Okada M., Nishiyama Y. Correlation of 18F-FDG and 11C-methionine uptake on PET/CT with Ki-67 immunohistochemistry in newly diagnosed intracranial meningiomas. Annals of nuclear medicine. 2018. 32 (9): 627–633.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Palmisciano P., Watanabe G., Conching A., Ogasawara C., Ferini G., Bin-Alamer O., Haider A. S., Sabini M. G., Cuttone G., Cosentino S., Ippolito M., Umana G. E. The role of 68GaGa-DOTA-SSTR PET radiotracers in brain tumors: a systematic review of the literature and ongoing clinical trials. Cancers. 2022. 14 (12).</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Perlow H.K., Siedow M., Gokun Y., McElroy J., Matsui J., Zoller W., Beyer S., Arnett A., Blakaj D., Boulter D., Fritz J., Miller E., Raval R., Kleefisch C., Bovi J., Palmer J.D. 68Ga-DOTATATE PET-based radiation contouring creates more precise radiation volumes for patients with meningioma. Int J Radiat Oncol Biol Phys. 2022. 113 (4):859–865.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Rachinger W., Stoecklein V.M., Terpolilli N.A., Haug A.R., Ertl L., Pöschl J., Schüller U., Schichor C., Thon N., Tonn J.-C. Increased 68Ga-DOTATATE uptake in PET imaging discriminates meningioma and tumorfree tissue. Journal of nuclear medicine: official publication, Society of Nuclear Medicine. 2015. 56 (3):347– 353.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Rogers L., Barani I., Chamberlain M., Kaley T.J., McDermott M., Raizer J., Schiff D., Weber D.C., Wen P.Y., Vogelbaum M. A. Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review. Journal of neurosurgery. 2015. 122 (1):4–23.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Ryttlefors M., Danfors T., Latini F., Montelius A., Blomquist E., Gudjonsson O. Long-term evaluation of the effect of hypofractionated high-energy proton treatment of benign meningiomas by means of (11) C–L-methionine positron emission tomography. European journal of nuclear medicine and molecular imaging. 2016. 43 (8):1432–1443.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Slot K.M., Verbaan D., Buis D.R., Schoonmade L.J., Berckel B.N.M., Vandertop W.P. Prediction of meningioma WHO Grade Using PET findings: a systematic review and meta-analysis. Journal of neuroimaging: official journal of the American Society of Neuroimaging. 2021. 31 (1):6–19.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Verger A., Kas A., Darcourt J., Guedj E. PET imaging in neuro-oncology: an update and overview of a rapidly growing area. Cancers. 2022. 14 (5).</mixed-citation></ref></ref-list></back></article>
